Officials with Imprimis Pharmaceuticals have announced that they have made available a compounded formulation of pyrimethamine and leucovorin as a lower-cost alternative to pyrimethamine (Daraprim, Turing Pharmaceuticals).

In August 2015, Turing Pharmaceuticals obtained the exclusive rights to market pyrimethamine in the United States and increased the price from $13.50 per tablet to a reported $750 per tablet. 

Officials with Imprimis stated that they are offering a customizable compounded formulation of pyrimethamine and leucovorin in oral capsules starting at $99.00 for a 100-count bottle.

This formulation is a folic acid antagonist indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide; acute malaria in combination with other antimalarials only; and chemoprophylaxis of malaria due to susceptible strains of plasmodia.

This article originally appeared on MPR